Xuanzhu Biopharmaceutical Co., Ltd.
軒竹生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2575)

VOLUNTARY ANNOUNCEMENT XUANYUENING, AN INNOVATIVE DRUG, FIRST INCLUDED IN THE NRDL

The board of directors (the "**Board**") of Xuanzhu Biopharmaceutical Co., Ltd. (the "**Company**" or "**Xuanzhu Biopharmaceutical**", together with its subsidiaries, collectively referred to as the "**Group**") is pleased to announce that the Company's independently developed innovative drug, Bireociclib Tablets (brand name: Xuanyuening), has been included for the first time in the National Reimbursement Drug List for Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance (2025) (the "**2025 NRDL**"). The 2025 NRDL will officially take effect on January 1, 2026.

The Company is able to further enhance the affordability and accessibility of Xuanyuening among patients after the discussion on the medical insurance, which will facilitate the promotion of its market presence and increase sales volume, resulting in a significant impact on the long-term business development of the Company. The Company will make a cooperative effort to implement medical insurance policies, continue to promote the admission of hospitals, expand the core market and broaden market coverage, with a view to continuously improving drug accessibility for patients.

ABOUT BIREOCICLIB

Bireociclib Tablets (brand name: Xuanyuening), as a novel CDK2/4/6 inhibitor, possesses a unique multi-target synergistic mechanism of action, offering advantages such as potent inhibition of tumor cell proliferation and a significant reduction in hematological toxicity commonly associated with traditional CDK4/6 inhibitors. Bireociclib was approved by the National Medical Products Administration on May 2025, for use in combination with Fulvestrant for the treatment of patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) ("**HR+/HER2-**") advanced or metastatic breast cancer whose disease has progressed after prior endocrine therapy, and as a monotherapy for HR+/HER2- advanced or metastatic breast cancer patients who have progressed after receiving two or more lines of endocrine therapies and one chemotherapy in the metastatic stage, making it the first and only CDK4/6 inhibitor in China approved for a monotherapy indication. Two approved indications have been included in the 2025 NRDL. In addition to the two approved indications mentioned above, the supplemental new drug application ("S**NDA**") for Bireociclib in combination with aromatase inhibitor (AI) for the first-line treatment of HR+/HER2-advanced breast cancer is under review.

This announcement is made by the Company on a voluntary basis to update the investors of the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board
Xuanzhu Biopharmaceutical Co., Ltd.
Ms. Xu Yanjun
Chairperson of the Board and executive Director

Hong Kong, December 8, 2025

As of the date of this announcement, the board of directors of the Company comprises (i) Ms. Xu Yanjun, Dr. Li Jia Kui and Dr. Shih Cheng-Kon as executive Directors; (ii) Ms. Li Huiying, Mr. Yu Lifeng and Ms. Chen Yanling as non-executive Directors; and (iii) Mr. Liu Shuo, Ms. Wang Yu and Mr. Fan Chi Chiu as independent non-executive Directors.